Drug intelligence / Profile preview

CER-002

Development stage: Unknown
Lead developer: ABIONYX Pharma
Modality: Small Molecules
Administration: Oral

Overview

CER-002 is a small molecule, selective peroxisome proliferator-activated receptor delta (PPAR delta) agonist being developed for the treatment of cardiovascular and metabolic diseases. Originally licensed from Nippon Chemiphar by ABIONYX Pharma (formerly Cerenis Therapeutics), the compound aims to elevate HDL cholesterol levels and halt the progression of atherosclerosis. In preclinical studies, it demonstrated efficacy in lipid modulation and vascular protection. A Phase I clinical trial has been completed, showing that the drug was safe and well-tolerated across all tested doses.

Targets

PPARD (Peroxisome proliferator–activated receptor delta)

Beyond the preview

Go deeper on CER-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CER-002.

Explore the full profile